Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 62Myelodysplastic Syndromes 33Leukemia, Myelomonocytic, Chronic 16Leukemia 16Recurrence 9Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myelomonocytic, Acute 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Monocytic, Acute 5Hodgkin Disease 5Myeloproliferative Disorders 4Congenital Abnormalities 4Anemia, Refractory, with Excess of Blasts 4Thrombocythemia, Essential 3Primary Myelofibrosis 3Polycythemia Vera 3Lymphoma 3Blast Crisis 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Fluorouracil 8Bevacizumab 8Oxaliplatin 7Leucovorin 7Irinotecan 7Capecitabine 7Cetuximab 6Panitumumab 4sintilimab 2regorafenib 2aflibercept 2tremelimumab 1spartalizumab 1pembrolizumab 1irinotecan sucrosofate 1durvalumab 1camrelizumab 1atezolizumab 1anisodamine 1SHR-1701 1Radiotherapy 1Pemetrexed 1Nivolumab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methotrexate 1Lycopene 1Loperamide 1Ipilimumab 1HMPL-013 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Cancer Metastatic × Decitabine × Clear all
NCT07007767 2025-06-06

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
32 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡